Clinical Evaluation of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement (CADENCE)
← catalyst calendarSponsored by Smith & Nephew, Inc. (industry) · SNN — their whole pipeline →.
Phase
—
Status
Suspended
Study type
Observational
Enrollment
132actual
Sites
11
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Prematurely terminated -Sponsor decision not due to adverse events, complications, or device issues. Final data collection underway.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-08-24 | actual | When the study began enrolling |
| Primary completion | 2025-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2017-05-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis
- Degenerative Arthritis
- Post Traumatic Arthritis
Intervention
- Device: Integra Cadence Total Ankle System — also filed as Primary Ankle Arthroplasty
Primary outcome
what the primary-completion date above is the date OFImplant Survivorship
measured 2 years
Permalink · SNN's whole pipeline · Catalyst calendar · Every registered study · What changed